{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:14:02Z","timestamp":1790709242556,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,7]]},"DOI":"10.7759\/cureus.28916","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T02:51:55Z","timestamp":1662605515000},"source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Paul","family":"Foucambert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith D","family":"Esbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Panthangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne R","family":"Cyril Kurupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjumol","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahrukh","family":"Shahbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halah","family":"Almatooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/PAF.0000000000000236","article-title":"Lethal dengue virus infection: a forensic overview","volume":"37","author":"Byard RW","year":"2016","unstructured":"Byard RW. Lethal dengue virus infection: a forensic overview. Am J Forensic Med Pathol. 2016, 37:74-8. 10.1097\/PAF.0000000000000236","journal-title":"Am J Forensic Med Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.glohj.2019.06.002","article-title":"Dengue epidemiology","volume":"3","author":"Jing Q","year":"2019","unstructured":"Jing Q, Wang M. Dengue epidemiology. J Glob Health. 2019, 3:37-45. 10.1016\/j.glohj.2019.06.002","journal-title":"J Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-015-3624-1","article-title":"Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past","volume":"30","author":"Islam R","year":"2015","unstructured":"Islam R, Salahuddin M, Ayubi MS, Hossain T, Majumder A, Taylor-Robinson AW, Mahmud-Al-Rafat A. Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past. Virol Sin. 2015, 30:326-43. 10.1007\/s12250-015-3624-1","journal-title":"Virol Sin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2009.10.007","article-title":"Dengue virus","volume":"30","author":"Ross TM","year":"2010","unstructured":"Ross TM. Dengue virus. Clin Lab Med. 2010, 30:149-60. 10.1016\/j.cll.2009.10.007","journal-title":"Clin Lab Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1139\/cjm-2020-0572","article-title":"Dengue virus: epidemiology, biology, and disease aetiology","volume":"67","author":"Roy SK","year":"2021","unstructured":"Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021, 67:687-702. 10.1139\/cjm-2020-0572","journal-title":"Can J Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6803098","article-title":"Dengue fever: causes, complications, and vaccine strategies","volume":"2016","author":"Khetarpal N","year":"2016","unstructured":"Khetarpal N, Khanna I. Dengue fever: causes, complications, and vaccine strategies. J Immunol Res. 2016, 2016:6803098. 10.1155\/2016\/6803098","journal-title":"J Immunol Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-82501-6.00002-5","article-title":"Dengue virus","author":"Beltz LA","year":"2021","unstructured":"Beltz LA. Dengue virus. Zika and other neglected and emerging flaviviruses. Beltz LA (ed): Elsevier B.V., Amsterdam, Netherlands; 2021. 19-39. 10.1016\/B978-0-323-82501-6.00002-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7020-5101-2.00016-9","article-title":"Dengue","author":"Yacoub S","year":"2014","unstructured":"Yacoub S, Farrar J. Dengue. Manson\u2019s tropical infectious diseases (twenty-third edition). Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ (ed): W.B. Saunders, Philadelphia, United States; 2014. 162-70. 10.1016\/B978-0-7020-5101-2.00016-9"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1248405","article-title":"Current management of severe dengue infection","volume":"15","author":"Lee TH","year":"2017","unstructured":"Lee TH, Lee LK, Lye DC, Leo YS. Current management of severe dengue infection. Expert Rev Anti Infect Ther. 2017, 15:67-78. 10.1080\/14787210.2017.1248405","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/25151355211015839","article-title":"Dengvaxia: the world's first vaccine for prevention of secondary dengue","volume":"9","author":"Tully D","year":"2021","unstructured":"Tully D, Griffiths CL. Dengvaxia: the world's first vaccine for prevention of secondary dengue. Ther Adv Vaccines Immunother. 2021, 9:25151355211015839. 10.1177\/25151355211015839","journal-title":"Ther Adv Vaccines Immunother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.12932\/AP-100518-0309","article-title":"Dengue vaccine: global development update","volume":"38","author":"Prompetchara E","year":"2020","unstructured":"Prompetchara E, Ketloy C, Thomas SJ, Ruxrungtham K. Dengue vaccine: global development update. Asian Pac J Allergy Immunol. 2020, 38:178-85. 10.12932\/AP-100518-0309","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas SJ","year":"2019","unstructured":"Thomas SJ, Yoon IK. A review of Dengvaxia\u00ae: development to deployment. Hum Vaccin Immunother. 2019, 15:2295-314. 10.1080\/21645515.2019.1658503","journal-title":"Hum Vaccin Immunother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine?","volume":"15","author":"Whitehead SS","year":"2016","unstructured":"Whitehead SS. Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine?. Expert Rev Vaccines. 2016, 15:509-17. 10.1586\/14760584.2016.1115727","journal-title":"Expert Rev Vaccines"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal S","year":"2019","unstructured":"Biswal S, Reynales H, Saez-Llorens X, et al.. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019, 381:2009-19. 10.1056\/NEJMoa1903869","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding MR","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro SRS, et al.. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014, 384:1358-65. 10.1016\/S0140-6736(14)61060-6","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar L","year":"2015","unstructured":"Villar L, Dayan GH, Arredondo-Garc\u00eda JL, et al.. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015, 372:113-23. 10.1056\/NEJMoa1411037","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon A","year":"2012","unstructured":"Sabchareon A, Wallace D, Sirivichayakul C, et al.. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet. 2012, 380:1559-67. 10.1016\/S0140-6736(12)61428-7","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/1995-7645.267582","article-title":"Long-term safety follow-up of children from a randomized\u2014controlled phase II b proof\u2014of\u2014concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD\u2014TDV) in Thailand","volume":"12","author":"Limkittikul K","year":"2019","unstructured":"Limkittikul K, Hattasingh W, Chansinghakul D, et al.. Long-term safety follow-up of children from a randomized\u2014controlled phase II b proof\u2014of\u2014concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD\u2014TDV) in Thailand. Asian Pac J Trop Med. 2019, 12:396-403. 10.4103\/1995-7645.267582","journal-title":"Asian Pac J Trop Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal S","year":"2020","unstructured":"Biswal S, Borja-Tabora C, Martinez Vargas L, et al.. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020, 395:1423-33. 10.1016\/S0140-6736(20)30414-1","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata CF","year":"2012","unstructured":"Lanata CF, Andrade T, Gil AI, et al.. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012, 30:5935-41. 10.1016\/j.vaccine.2012.07.043","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou V","year":"2020","unstructured":"Tricou V, S\u00e1ez-Llorens X, Yu D, et al.. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020, 395:1434-43. 10.1016\/S0140-6736(20)30556-0","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7560.1000162","article-title":"Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children","volume":"3","author":"Tran NH","year":"2012","unstructured":"Tran NH, Luong CQ, Vu TQH, et al.. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012, 3:162. 10.4172\/2157-7560.1000162","journal-title":"J Vaccines Vaccin"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garc\u00eda JL","year":"2018","unstructured":"Arredondo-Garc\u00eda JL, Hadinegoro SR, Reynales H, et al.. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018, 24:755-63. 10.1016\/j.cmi.2018.01.018","journal-title":"Clin Microbiol Infect"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab288","article-title":"Analysis of hospitalized and severe dengue cases over the 6 years of follow-up of the tetravalent dengue vaccine (CYD-TDV) efficacy trials in Asia and Latin America","volume":"73","author":"Forrat R","year":"2021","unstructured":"Forrat R, Dayan GH, DiazGranados CA, et al.. Analysis of hospitalized and severe dengue cases over the 6 years of follow-up of the tetravalent dengue vaccine (CYD-TDV) efficacy trials in Asia and Latin America. Clin Infect Dis. 2021, 73:1003-12. 10.1093\/cid\/ciab288","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.042","article-title":"Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: a case-control study","volume":"39","author":"Ylade M","year":"2021","unstructured":"Ylade M, Agrupis KA, Daag JV, et al.. Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: a case-control study. Vaccine. 2021, 39:5318-25. 10.1016\/j.vaccine.2021.07.042","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns PB","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011, 128:305-10. 10.1097\/PRS.0b013e318219c171","journal-title":"Plast Reconstr Surg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, September 2018 - recommendations","volume":"37","year":"2019","unstructured":"Dengue vaccine. WHO position paper, September 2018 - recommendations. Vaccine. 2019, 37:4848-9. 10.1016\/j.vaccine.2018.09.063","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman MG","year":"2013","unstructured":"Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013, 158:1445-59. 10.1007\/s00705-013-1645-3","journal-title":"Arch Virol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar S","year":"2018","unstructured":"Sridhar S, Luedtke A, Langevin E, et al.. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018, 379:327-40. 10.1056\/NEJMoa1800820","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick LC","year":"2017","unstructured":"Katzelnick LC, Gresh L, Halloran ME, et al.. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017, 358:929-32. 10.1126\/science.aan6836","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1333211","article-title":"Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4\u00a0y after vaccination","volume":"13","author":"Vigne C","year":"2017","unstructured":"Vigne C, Dupuy M, Richetin A, et al.. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4\u00a0y after vaccination. Hum Vaccin Immunother. 2017, 13:2004-16. 10.1080\/21645515.2017.1333211","journal-title":"Hum Vaccin Immunother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/105177-efficacy-of-dengue-vaccines-in-the-prevention-of-severe-dengue-in-children-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:46:47Z","timestamp":1707490007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/105177-efficacy-of-dengue-vaccines-in-the-prevention-of-severe-dengue-in-children-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.28916","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,7]]}}}